The recognition of susceptibility to apoptosis as a major factor in tumorigenesis and tumor response to therapy has significantly changed current concepts of the formation of malignant brain tumors and of the basis of their striking resistance to current approaches of therapy. Loss of wild-type p53 activity was the first instance of a defect in the molecular machinery regulating susceptibility to apoptosis that was linked to the progression of gliomas and possibly their resistance to therapy. Further, expression of the antiapoptotic bcl-2 protein is likely to play a role in the failure of malignant gliomas to respond to radiotherapy and chemotherapy. The role of bcl-2 in the tumorigenesis and malignant progression of astrocytic tumors remains controversial. Targeting the CD95 pathway, a powerful endogenous system to regulate cell survival via induction of apoptosis, is a promising novel approach of immunotherapy for malignant gliomas.

Journal Section:
Original Paper
Keywords:
Malignant glioma, Apoptosis, bcl-2, p53, CD95(Fas/APO-l)
This content is only available via PDF.
© 1996 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
1996
You do not currently have access to this content.